Page 3 - Gene Therapy Program News Today

Theyve had a lifetime of wear. Look at this patient. Shes young. Through a variety of bad things that have happened to her, shes lost all of her back teeth. She has an executive position. She believes its holding her back, because she wont even speak up in a meeting for fear of smiling. Shes embarrassed of her smile. And showing that she has no back teeth. Exactly. And you talk about lost Human Potential in such a young person. And in one day one day we can help her. Wow. She looked like a kid, ...

Compulsive hoarder. Runners on your mark . Music . Get set . Youre rolled out at the dawning of the day . sfx starter pistol shot . Heart racin as you made your little get away . But theres always scars, when you fall back far . . We lose our way, we get back up again . . Its never too late to get back up again . . One day, youre gonna shine again, . . You may be knocked down but not out forever . Again . . And one day. . Well, tonight we have a rare interview with an american who became a leade...

Sana Biotechnology (NASDAQ:SANA – Get Free Report) and Passage Bio (NASDAQ:PASG – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Volatility & Risk Sana Biotechnology has a […]

Thanks to gene therapies like Casgevy and Elevidys, there is new hope for seemingly incurable diseases, but the treatments will be truly revolutionary only if they are available to everyone.

- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study ...

ECUR-506 is a gene editing-based investigational therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency

VANCOUVER, BC, Dec. 4, 2023 /PRNewswire/ - PreveCeutical Medical Inc.   , is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy...

A podcast, Netflix series, and TV adaptation examine regenerative medicine doctor's wrongdoings

PHILADELPHIA, Nov. 17, 2023 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced...

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment ...